5
|
Mannic T, Satta N, Pagano S, Python M, Virzi J, Montecucco F, Frias MA, James RW, Maturana AD, Rossier MF, Vuilleumier N. CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes. Endocrinology 2015; 156:4707-19. [PMID: 26393305 DOI: 10.1210/en.2015-1605] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In vitro and animal studies point to autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) as possible mediators of cardiovascular (CV) disease involving several mechanisms such as basal heart rate interference mediated by a mineralocorticoid receptor-dependent L-type calcium channel activation, and a direct pro-inflammatory effect through the engagement of the toll-like receptor (TLR) 2/CD14 complex. Nevertheless, the possible implication of these receptors in the pro-arrhythmogenic effect of anti-apoA-1 antibodies remains elusive. We aimed at determining whether CD14 and TLRs could mediate the anti-apoA-1 IgG chronotropic response in neonatal rat ventricular cardiomyocytes (NRVC). Blocking CD14 suppressed anti-apoA-1 IgG binding to NRVC and the related positive chronotropic response. Anti-apoA-1 IgG alone induced the formation of a TLR2/TLR4/CD14 complex, followed by the phosphorylation of Src, whereas aldosterone alone promoted the phosphorylation of Akt by phosphatidylinositol 3-kinase (PI3K), without affecting the chronotropic response. In the presence of both aldosterone and anti-apoA-1 IgG, the localization of TLR2/TLR4/CD14 was increased in membrane lipid rafts, followed by PI3K and Src activation, leading to an L-type calcium channel-dependent positive chronotropic response. Pharmacological inhibition of the Src pathway led to the decrease of L-type calcium channel activity and abrogated the NRVC chronotropic response. Activation of CD14 seems to be a key regulator of the mineralocorticoid receptor-dependent anti-apoA-1 IgG positive chronotropic effect on NRVCs, involving relocation of the CD14/TLR2/TLR4 complex into lipid rafts followed by PI3K and Src-dependent L-type calcium channel activation.
Collapse
Affiliation(s)
- Tiphaine Mannic
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Nathalie Satta
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Sabrina Pagano
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Magaly Python
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Julien Virzi
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Fabrizio Montecucco
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Miguel A Frias
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Richard W James
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Andres D Maturana
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Michel F Rossier
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Nicolas Vuilleumier
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| |
Collapse
|